Bacterial vaginosis: treatment with topical intravaginal clindamycin phosphate.
We tested topical intravaginal clindamycin phosphate at concentrations of 0.1, 1.0, and 2.0% in the treatment of 62 women with symptomatic bacterial vaginosis in a prospective, randomized, double-blind, placebo-controlled trial, and offered open-label treatment with 1.0% clindamycin to patients with persistent disease after blinded treatment. Blinded intravaginal clindamycin phosphate treatment cured bacterial vaginosis in 93.5% (43 of 46) of patients 4-7 days after therapy, compared with 25.0% (four of 16) of patients receiving placebo (P less than .001). One month later, 89.7% (35 of 39) of those who initially responded to clindamycin treatment showed persistent cure. There were no significant side effects.
Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
C H
CH
Livengood
J L
JL
Thomason
G B
GB
Hill
D000282:Administration, Intravaginal; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D014627:Vaginitis / Q000188:drug therapy* / Q000382:microbiology
D002981:Clindamycin; C007084:clindamycin phosphate